The Aptamer group of companies focuses on the development of aptamer technologies. We develop nucleic acid aptamers for use in research & development, biomarker discovery, diagnostics or therapeutic developments. Aptamers are short ssDNA or ssRNA sequences that offer high-affinity and specificity to virtually all types of targets. Aptamers are versatile, cost effective and offer a complementary or alternative solution to antibodies. We have over 25 years combined expertise in the development of nucleic acid aptamers to peptides, proteins, cells, tissue samples, micro-organisms and small molecules.
Aptamers have many advantages over traditional methods such antibody based assays in that they are isolated entirely in vitro, in a fraction of the time required for novel antibodies. As well as the obvious time saving, in vitro isolation gives a greater degree of control over the function, affinity and specificity of the resulting aptamers. In addition, they are more readily modified, facilitating their use in the development of simpler diagnostic / detection platforms and a streamlined, cost efficient approach to therapeutic development.
The founders have over 25 combined years in R&D in both the academic and commercial sectors and have a high level of expertise in the development of ssDNA & RNA aptamers. Arron Tolley (CEO and founder) has considerable experience in biophysics, molecular biology and assay development with a background in molecular medicine. He has expertise to the field of ssDNA and ssRNA aptamers isolated against live cell line models of oesophageal cancer.
